5.8 Infections & Malignancy After Liver Transplant

Summary: Infections & Malignancy After Liver Transplant

Lecture by Prof. Sanjaya Satapathy, MD, FAASLD | Transplant Hepatology Board Review Series

1. Main Clinical Topics Discussed

• Net state of immunosuppression as a foundational framework in transplant medicine
• Temporal patterns of infection after liver transplantation
• Immunosuppression adjustment strategies during infection, sepsis, and malignancy
• Post-transplant lymphoproliferative disorder (PTLD) and other malignancies
• Drug-drug interactions relevant to transplant pharmacology

2. Key Learning Points, Guidelines, and Recommendations

Net State of Immunosuppression

• Infection and malignancy risk is not determined solely by the written immunosuppressive regimen
• Reflects total cumulative immunologic burden, incorporating:

- Intensity of induction therapy (e.g., lymphocyte-depleting agents such as ATG)

- Current CNI levels and doses

- Recent rejection treatment (pulse steroids, anti-thymocyte globulin)

- Time since transplantation

- CMV serostatus and prophylaxis coverage

- Host factors: leukopenia, malnutrition, renal failure

- Local factors: invasive devices, surgical wounds, biliary complications

• Board Pearl: Two patients on identical regimens may have vastly different infection risks

Temporal Patterns of Post-Transplant Infection

• 0–1 Month (Early): Nosocomial/surgical infections predominate

- Bacterial infections, *Candida*, line-related infections

- Biliary leaks, intra-abdominal abscesses, post-operative pneumonia

- Primarily procedure-related, not opportunistic

• 1–6 Months (Intermediate — "Opportunistic Window"):

- CMV, *Pneumocystis jirovecii* pneumonia (PCP), select fungal infections

- Risk dramatically elevated if patient received recent rejection therapy

• >6 Months (Late):

- Predominantly community-acquired pathogens in stable patients

- Opportunistic infections persist if patient remains heavily immunosuppressed or has chronic CMV

Immunosuppression Adjustment During Serious Infection/Sepsis

• Step 1: Treat infection aggressively — obtain cultures, initiate broad-spectrum antimicrobials
• Step 2: Identify infection source (biliary complications, central lines, pulmonary, intra-abdominal)
• Step 3: Sequential immunosuppression reduction:

- First: Reduce or hold anti-metabolite (mycophenolate mofetil [MMF] or azathioprine)

- Contributes to leukopenia; rapid effect on bone marrow recovery

- Second: Minimize corticosteroids when clinically safe

- Third: Maintain CNI (tacrolimus/cyclosporine) at lower end of therapeutic range — avoid abrupt withdrawal to prevent acute rejection

• In life-threatening infection, more aggressive reduction may be necessary

Leukopenia Management

• Most common culprit: MMF — hold or reduce first
• Review other bone marrow–suppressing agents: valganciclovir (CMV prophylaxis/treatment), trimethoprim-sulfamethoxazole (PCP prophylaxis)
• Consider G-CSF (filgrastim) for severe leukopenia or active infection
• Board Pearl: Low WBC in a transplant patient = drug effect until proven otherwise

CMV Infection

• Frequently a marker of excessive immunosuppression, not merely an isolated infection
• Management: dual-track approach

- Antiviral therapy: ganciclovir or valganciclovir

- Reduce immunosuppression — typically MMF first

• Classic board pattern: CMV + leukopenia + diarrhea → consider MMF–valganciclovir interaction

Invasive Fungal Infections

• Associated with high mortality; occur in profoundly immunosuppressed patients
• Risk factors: high-dose/repeated steroid use, multiple rejection episodes, post-operative complications (biliary leaks, prolonged ICU stay)
• Management: antifungal